CHAPEL HILL, N.C.--(BUSINESS WIRE)--POZEN Inc.’s (NASDAQ:POZN) PA32520 product candidate (enteric coated aspirin 325 mg with immediate release omeprazole 20 mg) may provide less upper gastrointestinal mucosal damage usually associated with higher doses of aspirin therapy, and may allow for treatment with higher doses of aspirin (up to 325 mg/daily) to maximize cardiovascular protection, according to new data presented today at the American Heart Association’s (AHA) Scientific Sessions 2008 in New Orleans, Louisiana. Findings from two similar studies, which included 160 subjects, showed that treatment with enteric coated aspirin alone is associated with a high prevalence of upper gastrointestinal damage. This damage is reduced with PA32520 therapy as referenced in the study abstract.
